Intervention

ZD4054

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions5

Lead sponsors shown5

Clinical trials

8 shown

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate CancerNCT01119118 · 2010-04-01

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate CancerNCT01000948 · 2009-10-01

Window Study of ZD4054 in Metastatic Prostate CancerNCT01168141 · 2009-07-01

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer StudyNCT00745875 · 2008-08-01

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate CancerNCT00617669 · 2008-01-01

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate CancerNCT00626548 · 2008-01-01

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone MetastasesNCT00554229 · 2007-11-01

Carboplatin With or Without ZD4054 in Patients With Metastatic Breast CancerNCT01134497

Common conditions

Prostate Cancer6 Metastasis2 Lung Cancer1 Metastatic Breast Cancer1 Non Small Cell Lung Cancer1

Leading sponsors

AstraZeneca4 Aarhus University Hospital1 Cardiff University1 The Christie NHS Foundation Trust1 University of Wisconsin, Madison1

Trial status mix

COMPLETED3

TERMINATED3

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE24

PHASE33

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.